NASDAQ: EXASExact Sciences Corp Stock
$55.13+0.34 (+0.62%)
Updated Jan 23, 2025
EXAS Price
$55.13
Fair Value Price
N/A
Market Cap
$10.20B
52 Week Low
$40.62
52 Week High
$79.62
P/E
-47.12x
P/B
3.18x
P/S
4.68x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.69B
Earnings
-$214.04M
Gross Margin
73%
Operating Margin
-6.88%
Profit Margin
-7.9%
Debt to Equity
1.1
Operating Cash Flow
$233M
Beta
1.25
Next Earnings
Feb 19, 2025
Ex-Dividend
N/A
Next Dividend
N/A
EXAS Overview
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EXAS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Value
C
Growth
D
Momentum
D
Sentiment
C
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important EXAS news, forecast changes, insider trades & much more!
EXAS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EXAS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EXAS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EXAS is good value based on its book value relative to its share price (3.18x), compared to the US Diagnostics & Research industry average (4.23x)
P/B vs Industry Valuation
EXAS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more EXAS due diligence checks available for Premium users.
Valuation
EXAS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-47.12x
Industry
25.39x
Market
30.03x
EXAS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.18x
Industry
4.23x
EXAS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EXAS's financial health
Profit margin
Revenue
$708.7M
Net Income
-$38.2M
Profit Margin
-5.4%
EXAS's Earnings (EBIT) of -$185.27M... subscribe to Premium to read more.
Interest Coverage Financials
EXAS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.7B
Liabilities
$3.5B
Debt to equity
1.1
EXAS's short-term assets ($1.53B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EXAS's long-term liabilities ($2.81B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EXAS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
EXAS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$138.7M
Investing
-$81.7M
Financing
-$226.0k
EXAS's operating cash flow ($233.02M)... subscribe to Premium to read more.
Debt Coverage Financials
EXAS vs Diagnostic & Research Stocks
Exact Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.